BiotechTube

ateganosine + Cadonilimab

Phase 1Recruiting
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Resectable Hepatocellular Carcinoma

Conditions

Resectable Hepatocellular Carcinoma

Trial Timeline

May 1, 2026 → May 1, 2031

NCT ID
NCT07446257

About ateganosine + Cadonilimab

ateganosine + Cadonilimab is a phase 1 stage product being developed by MAIA Biotechnology for Resectable Hepatocellular Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07446257. Target conditions include Resectable Hepatocellular Carcinoma.

What happened to similar drugs?

1 of 20 similar drugs in Resectable Hepatocellular Carcinoma were approved

Approved (1) Terminated (0) Active (19)
✅DurvalumabAstraZenecaApproved
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3
🔄CamrelizumabJiangsu Hengrui MedicinePhase 3
🔄SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07446257Phase 1Recruiting

Competing Products

20 competing products in Resectable Hepatocellular Carcinoma

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
26
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
ASP1948Astellas PharmaPhase 1
29
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
42
LenvatinibEisaiPhase 2
35
LenvatinibEisaiPhase 1
29
LenvatinibEisaiPhase 1/2
36
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
ONO-7913 + ONO-4538 + Fluorouracil + Oxaliplatin + Levofolinate + Bevacizumab + CetuximabOno PharmaceuticalPhase 1
33
SHR-4602Jiangsu Hengrui MedicinePhase 2
42
CamrelizumabJiangsu Hengrui MedicinePhase 3
47
SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
40
SHR-1210Jiangsu Hengrui MedicinePhase 2
35